# Hematopoietic Stem Cell Transplantation

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/hematopoietic-stem-cell-transplantation/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the biology, regulation, and clinical applications of hematopoietic stem cells (HSCs) within the bone marrow niche. It covers topics such as HSC quiescence, stem cell aging, graft-versus-host disease, hematologic malignancies, and the role of mesenchymal stem cells in supporting HSC function. Additionally, it explores the mechanisms of stem cell mobilization and transplantation for therapeutic purposes. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t10345 |
| Works | 211 |

## Topic papers all

Showing 15 of 211.

- [National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report](https://scholariq.org/papers/national-institutes-of-health-consensus-development-project-on-criteria-for/)
- [Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer](https://scholariq.org/papers/successful-adoptive-transfer-and-in-vivo-expansion-of-human-haploidentical-nk/)
- [Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects](https://scholariq.org/papers/hematopoietic-cell-transplantation-in-older-patients-with-hematologic/)
- [Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis](https://scholariq.org/papers/prostaglandin-e2-regulates-vertebrate-haematopoietic-stem-cell-homeostasis/)
- [Age, Thymopoiesis, and CD4+ T-Lymphocyte Regeneration after Intensive Chemotherapy](https://scholariq.org/papers/age-thymopoiesis-and-cd4-t-lymphocyte-regeneration-after-intensive-chemotherapy/)
- [2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines](https://scholariq.org/papers/2000-update-of-recommendations-for-the-use-of-hematopoietic-colony-stimulating/)
- [Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival](https://scholariq.org/papers/transplantation-of-unrelated-donor-umbilical-cord-blood-in-102-patients-with/)
- [Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region](https://scholariq.org/papers/chemotherapy-resistant-human-aml-stem-cells-home-to-and-engraft-within-the-bone/)
- [Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes](https://scholariq.org/papers/therapy-related-clonal-hematopoiesis-in-patients-with-non-hematologic-cancers-is/)
- [Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors.](https://scholariq.org/papers/interleukin-6-enhancement-of-interleukin-3-dependent-proliferation-of/)
- [Transplantation Outcomes for Severe Combined Immunodeficiency, 2000–2009](https://scholariq.org/papers/transplantation-outcomes-for-severe-combined-immunodeficiency-2000-2009/)
- [Cancer therapy shapes the fitness landscape of clonal hematopoiesis](https://scholariq.org/papers/cancer-therapy-shapes-the-fitness-landscape-of-clonal-hematopoiesis/)
- [Current Use of and Trends in Hematopoietic Cell Transplantation in the United States](https://scholariq.org/papers/current-use-of-and-trends-in-hematopoietic-cell-transplantation-in-the-united/)
- [Risk factors for acute GVHD and survival after hematopoietic cell transplantation](https://scholariq.org/papers/risk-factors-for-acute-gvhd-and-survival-after-hematopoietic-cell/)
- [Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report](https://scholariq.org/papers/therapeutic-drug-monitoring-of-tacrolimus-personalized-therapy-second-consensus/)

## Topic primary papers

Showing 15 of 99.

- [National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report](https://scholariq.org/papers/national-institutes-of-health-consensus-development-project-on-criteria-for/)
- [Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects](https://scholariq.org/papers/hematopoietic-cell-transplantation-in-older-patients-with-hematologic/)
- [Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival](https://scholariq.org/papers/transplantation-of-unrelated-donor-umbilical-cord-blood-in-102-patients-with/)
- [Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region](https://scholariq.org/papers/chemotherapy-resistant-human-aml-stem-cells-home-to-and-engraft-within-the-bone/)
- [Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors.](https://scholariq.org/papers/interleukin-6-enhancement-of-interleukin-3-dependent-proliferation-of/)
- [Current Use of and Trends in Hematopoietic Cell Transplantation in the United States](https://scholariq.org/papers/current-use-of-and-trends-in-hematopoietic-cell-transplantation-in-the-united/)
- [Risk factors for acute GVHD and survival after hematopoietic cell transplantation](https://scholariq.org/papers/risk-factors-for-acute-gvhd-and-survival-after-hematopoietic-cell/)
- [Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells](https://scholariq.org/papers/exit-from-dormancy-provokes-dna-damage-induced-attrition-in-haematopoietic-stem/)
- [Effect of Matching of Class I HLA Alleles on Clinical Outcome after Transplantation of Hematopoietic Stem Cells from an Unrelated Donor](https://scholariq.org/papers/effect-of-matching-of-class-i-hla-alleles-on-clinical-outcome-after/)
- [Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation](https://scholariq.org/papers/loss-of-mismatched-hla-in-leukemia-after-stem-cell-transplantation/)
- [Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation](https://scholariq.org/papers/composite-end-point-of-graft-versus-host-disease-free-relapse-free-survival/)
- [Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research](https://scholariq.org/papers/increasing-incidence-of-chronic-graft-versus-host-disease-in-allogeneic/)
- [Normal and Leukemic Stem Cell Niches: Insights and Therapeutic Opportunities](https://scholariq.org/papers/normal-and-leukemic-stem-cell-niches-insights-and-therapeutic-opportunities/)
- [Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation](https://scholariq.org/papers/indications-for-autologous-and-allogeneic-hematopoietic-cell-transplantation/)
- [Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation](https://scholariq.org/papers/cyclophosphamide-metabolism-liver-toxicity-and-mortality-following-hematopoietic/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.